title: So Far, PCSK9 Inhibitors Work for All Heterozygous FH Patients.
authors.affiliation: From the Division of Pediatric Genetics & Metabolism (M.C.M.), and Division of Nutrition & Metabolic Diseases (Z.A.), Center for Human Nutrition, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX.
authors.forename: Markey C
authors.initials: MC
authors.lastname: McNutt
authors.affiliation: From the Division of Pediatric Genetics & Metabolism (M.C.M.), and Division of Nutrition & Metabolic Diseases (Z.A.), Center for Human Nutrition, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX. Zahid.ahmad@utsouthwestern.edu.
authors.forename: Zahid
authors.initials: Z
authors.lastname: Ahmad
mesh_terms: D006579:Heterozygote; D006801:Humans; D006937:Hypercholesterolemia; D006938:Hyperlipoproteinemia Type II; D011973:Receptors, LDL / Q000235:genetics
chemical_list: D011973:Receptors, LDL
keywords: Editorials; LDLR; PCSK9; cardiovascular disease; hypercholesterolemia; lipoprotein; pharmacology; treatment